VistaGen terminates President/CSO; PH94B Phase 3 trial completes enrollment

Vistagen Therapeutics, Inc.

President and CSO H. Ralph Snodgrass terminated effective June 15, 2022.
Last patient completed protocol in PALISADE-1 Phase 3 trial of PH94B for social anxiety disorder.
Topline results from PALISADE-1 expected mid-2022; PALISADE-2 topline expected late-2022.
FDA granted Fast Track designation for PH94B in social anxiety disorder.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

H. Ralph Snodgrass

President and Chief Scientific Officer

VTGN · Vistagen Therapeutics, Inc.

Effective: 2022-06-15
Filed: June 22, 2022, 7:59 PM ET

On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

H. Ralph Snodgrass was terminated as President and Chief Scientific Officer at Vistagen Therapeutics, Inc..

Action: terminated
Role: President and Chief Scientific Officer

Exact text from the filing

On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.

View on SEC.gov

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001851734-22-000341

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.